89bio Elects Directors and Approves Proposals at Annual Meeting

An announcement from 89bio ( (ETNB) ) is now available.

On May 28, 2025, 89bio, Inc. held its Annual Meeting of Stockholders where all director nominees were elected, and all proposals were approved. The meeting included the election of Class III Directors and the ratification of KPMG LLP as the independent auditor, reflecting strong shareholder support for the company’s governance and operational strategies.

The most recent analyst rating on (ETNB) stock is a Hold with a $12.00 price target. To see the full list of analyst forecasts on 89bio stock, see the ETNB Stock Forecast page.

Spark’s Take on ETNB Stock

According to Spark, TipRanks’ AI Analyst, ETNB is a Neutral.

The overall score for 89bio is primarily weighed down by the financial performance due to ongoing losses and cash flow issues. Technical indicators show bearish momentum, adding to the risk. Although corporate events highlight promising clinical progress, the company’s valuation remains low due to negative earnings, typical in the biotech industry. The stock reflects high-risk, high-reward potential.

To see Spark’s full report on ETNB stock, click here.

More about 89bio

89bio, Inc. operates in the biotechnology industry, focusing on developing innovative therapies for liver and cardio-metabolic diseases. The company aims to address significant unmet medical needs with its product pipeline.

Average Trading Volume: 2,008,045

Technical Sentiment Signal: Buy

Current Market Cap: $1.43B

For a thorough assessment of ETNB stock, go to TipRanks’ Stock Analysis page.